T-20 Small Program, CD4 <50, Will Enroll November 27 at 3:00 P.M.
A small safety study for patients with a CD4 count under 50 and who cannot construct a viable antiviral regimen with approved drugs will open for registration on November 27. Only the first 56 physicians who call in, and have exactly three eligible patients each, will be accepted.
Anthrax, Bioterrorism Fears Stimulate Immune, Other Research
The need for defense against biological warfare is pushing the development of new drugs that could fight many diseases. Many of these work by changing the body's immune response; others use different mechanisms. Some of the approaches now being studied are related to certain traditional or alternative treatments.
TheBody is a service of Remedy Health Media, 461 Fifth Avenue, 14th Floor, New York, NY 10017. TheBody and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBody's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBody is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.